Home

IPCA Laboratories Limited

NSE: IPCALAB

₹1,949.60
-1.14%
EOD snapshot

About IPCA Laboratories Limited

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetes, diabetology, emollients/protectives, fever, gastroenterology, haematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, regenerative, respiratory, rheumatology, and urology. The company also exports its products to Europe, Africa, the Americas, rest of Asia, the Commonwealth of Independent States, and Australasia. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

Healthcare · Drug Manufacturers - Specialty & Generic

Full scanner analysis & price chartMembers

Results

No scheduled results found for IPCALAB.

Historical quarterly results aren't available in the current data feed.

Corporate Actions

No recent corporate actions for IPCALAB.

Latest News · IPCA Laboratories Limited

Loading news…

More in Healthcare

All companies, by sector

Company overview assembled from NSE results / corporate-action feeds and market news. Not investment advice.